Effects of the TCF7L2 and KCNQ1 common variant on sulfonylurea response in type 2 diabetes mellitus patients: a preliminary pharmacogenetic study
Open Access
- 11 January 2022
- journal article
- research article
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 21 (1) , 133-139
Abstract
Background Type 2 diabetes mellitus (T2DM) is a common chronic condition characterized by high blood glucose levels which is caused by genetic and environmental factors. Currently, pharmacogenomics (PGx) is anticipated to enable the development of personalized treatment in a wide range of health issues. Sulfonylureas (SFUs) are among the oral anti-diabetic drugs that are very popular due to their low cost. Genetic variants in transcription factor 7 like 2 (TCF7L2) and potassium voltage-gated channel subfamily Q member 1 (KCNQ1) have been reported for altered therapeutic response to sulfonylurea. The aim of the present study is to evaluate any association between common genetic variant of the TCF7L2 and KCNQ1 (rs7903146 and rs2237892, respectively) and the response to sulfonylurea in a group of Iranian patients for the first time. Methods Genotyping was carried out in 30 T2DM patients who received sulfonylurea treatment for more than two months in addition to previous medication using the Sanger sequencing method. Results In 30 T2DM patients who received SFUs treatment, 60%, 33.3% and 6.7% had CC, CT and TT genotypes, respectively. After treatment, adjusted fasting blood sugar (FBS) mean reduction level in CT and TT carriers was lower than CC carriers. Adjusted hemoglobin A1c (HbA1c) mean reduction level was also lower in CT and TT compared with CC carriers, but, none of these differences were statistically significant. Genotype frequencies of TT, CT and CC genotypes of rs2237892 variant of KCNQ1 gene were 0 (0%), 3 (10%) and 27 (90%) respectively. Patients with CT and CC genotypes of rs2237892 variant had also similar changes in FBS (P=0.200) and HbA1c (P=0.436) after treatment with SFUs. Conclusions Genotypes of TCF7L2 and KCNQ1 common variant did not show any impact on the treatment response among T2DM patients receiving SFUs.Keywords
This publication has 25 references indexed in Scilit:
- Pharmacogenetics and personalized treatment of type 2 diabetesBiochemia Medica, 2013
- Association betweenTCF7L2Genotype and Glycemic Control in Diabetic Patients Treated with GliclazideInternational Journal of Endocrinology, 2013
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean populationClinica Chimica Acta, 2011
- TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetesBMC Medical Genetics, 2011
- Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2010
- Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic PatientsDiabetes Care, 2008
- Variation in TCF7L2 Influences Therapeutic Response to SulfonylureasDiabetes, 2007
- Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetesDiabetes Research and Clinical Practice, 2007
- A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Research, 1988